scholarly journals Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

Oncotarget ◽  
2017 ◽  
Vol 8 (29) ◽  
pp. 47305-47316 ◽  
Author(s):  
Carles Codony-Servat ◽  
Jordi Codony-Servat ◽  
Niki Karachaliou ◽  
Miguel Angel Molina ◽  
Imane Chaib ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Signal Transducer ◽  
Small Cell Lung ◽  
Stat3 Signaling ◽  
Egfr Mutant ◽  
Transcription 3

scholarly journals Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small-Cell Lung Cancer

2014 ◽  
Vol 9 (4) ◽  
pp. 488-496 ◽  
Author(s):  
Cheng-Yi Wang ◽  
Ting-Ting Chao ◽  
Wei-Tien Tai ◽  
Fang-Yu Chang ◽  
Wen-Pin Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Therapy ◽  
Signal Transducer ◽  
Small Cell Lung ◽  
Transcription 3

scholarly journals Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non–Small Cell Lung Cancer

2005 ◽  
Vol 11 (21) ◽  
pp. 7674-7682 ◽  
Author(s):  
Harnisha Dalwadi ◽  
Kostyantyn Krysan ◽  
Nathalie Heuze-Vourc'h ◽  
Mariam Dohadwala ◽  
David Elashoff ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Interleukin 6 ◽  
Small Cell ◽  
Cyclooxygenase 2 ◽  
Signal Transducer ◽  
Small Cell Lung ◽  
Transcription 3

scholarly journals BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

2021 ◽  
Vol 14 (2) ◽  
pp. 100961
Author(s):  
Fushun Fan ◽  
Minhua Zhou ◽  
Xiaolan Ye ◽  
Zhenxian Mo ◽  
Yaru Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antitumor Activity ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Egfr Mutant

scholarly journals Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhiyu Peng ◽  
Huahang Lin ◽  
Ke Zhou ◽  
Senyi Deng ◽  
Jiandong Mei
Keyword(s):  
Lung Cancer ◽  
Sensitivity Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Value ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutant ◽  
Egfr Tkis

Abstract Objective To investigate the predictive value of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Methods We conducted a systemic search of PubMed, EMBASE, and the Cochrane Library from 1 January 2000 to 30 August 2020, to identify related studies. We combined the hazard ratio (HR) and 95% confidence interval (CI) to assess the correlation of PD-L1 expression with progression-free survival (PFS) and overall survival (OS). We assessed the quality of the included studies by the Newcastle–Ottawa Scale (NOS). We performed subgroup analyses based on immunohistochemistry (IHC) scoring system, IHC antibodies, sample size, countries, and survival analysis mode. Sensitivity analysis and evaluation of publication bias were also performed. Results Twelve studies including 991 patients met the criteria. The mean NOS score was 7.42 ± 1.19. Patients with high PD-L1 expression was associated with poorer PFS (HR = 1.90; 95% CI = 1.16–3.10; P = 0.011), while there was no association between PD-L1 expression and OS (HR = 1.19; 95% CI = 0.99–1.43; P = 0.070). Subgroup analysis prompted IHC scoring systems, IHC antibodies, and sample size have important effects on heterogeneity. The pooled results were robust according to the sensitivity analysis. Conclusions The result of this meta-analysis suggested that PD-L1 expression might be a predictive biomarker for EGFR-mutant non-small cell lung cancer treated with EGFR-TKIs.

Sign in / Sign up

Export Citation Format

Share Document